We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 34 investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Please watch the video for more information
days to go: Expired investment: £964,550
Walsh Aviation Limited has plans to create a low altitude airborne data acquisition method using the latest in Gyroplane technology. They have a 20-20-20 target to be able to fly at an altitude of 20 meters above the vegetation canopy, with a speed of 20 knots and to provide the service profitably at £20 per line kilometre.   
days to go: Expired investment: £61,000
The go-to platform for people planning the most important purchase of their lives: a new home.
days to go: Expired investment: £103,008
Forth allows users to track their wellbeing to see what impact their lifestyle is having on their health. It allows users to maximise their performance during athletics, keep track of their inner health and focus on things they may need to work on for greater overall wellbeing. 
days to go: Expired investment: £165,760
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go: Expired investment: £165,627
Europe's largest marketplace for classic cars. In 2018, Car & Classic achieved revenues of £1.3m, with the value of vehicles sold exceeding £480m and their website is visited by 2.2m users every month. 60% of revenue is derived from data contracts, whilst the other 40% is generated via advertisements. Data contracts are held by Cazana, the owner of Car & Classic, which is a B2B platform that values every vehicle by performing machine learning algorithms. The company claims that hundreds of businesses utilise this data. The Financial Ombudsman has declared that this data is recommended to be used for vehicle valuations during insurance claim cases.
days to go: Expired investment: £1,541,590
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph